Skip to content

Clinical Observation of Umbilical Acupuncture as an Adjuvant Therapy for Simple Obesity and Investigation into Its Appetite Regulation Mechanisms

Clinical Observation of Umbilical Acupuncture as an Adjuvant Therapy for Simple Obesity and Investigation into Its Appetite Regulation Mechanisms

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001221
Enrollment
Unknown
Registered
2025-06-19
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Treatment group:XOWi-based Weight Loss Intervention with Adjunctive Umbilical Acupuncture
Control group:"XOWi Weight Management Plan + Recommended Acupuncture Plan from the Expert Consensus on TCM Diagnosis and Treatment of Obesity (2022)"

Sponsors

Shanghai Municipal Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 18-65 years; Meets the diagnostic criteria for simple obesity; Conforming to the diagnostic criteria of TCM syndrome elements Weight loss of < 5 kg within the last three months; Provision of voluntary written informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria included: 1. Secondary obesity caused by endocrine disorders (e.g. hypothyroidism Cushing's syndrome polycystic ovary syndrome)12; 2. Glycemic abnormalities defined as HbA1c >6.5% and/or fasting plasma glucose =7 mmol/L and/or 2-hour postprandial glucose =11.1 mmol/L; 3. Use of weight-impacting medications (glucocorticoids antiepileptic drugs psychotropic medications) within the past 3 months; 4. Current or recent (past 3 months) use of gut microbiota-modulating agents (antibiotics probiotic supplements NSAIDs proton pump inhibitors immunosuppressants); 5. Severe comorbidities including cardiovascular/cerebrovascular diseases hematologic disorders psychiatric illnesses or malignancies; 6. Significant hepatic/renal dysfunction (ALT/AST exceeding 2.5 times upper limit of normal; glomerular filtration rate <30 mL/min/1.73 m²); 7. Pregnancy lactation or planned pregnancy; 8. Participation in other clinical trials involving investigational drugs/devices within the past 3 months; 9. Previous weight loss interventions within the past 6 months.

Design outcomes

Primary

MeasureTime frame
Percentage of Body Weight Loss;Proportion of Subjects Achieving =5% Weight Loss;

Secondary

MeasureTime frame
Insulin resistance (Fasting serum insulin, fasting serum C- peptide, HOMA2-IR );Proportion of Subjects Achieving =10% Weight Loss;Changes in body composition (Waist circumference, Waist-Hip-Ratio, body fat percentage, body fat mass, trunk fat percentage, limb muscle mass percentage);Peptide, PYY;Body Fat Percentage (BFP);Body Mass Index(BMI); triglyceride, TG;rs-fMRI;low-density lipoprotein cholesterol (LDL-C);Ghrelin;total cholesterol, TC;Cholecystokinin (CCK);Three-Factor Eating Questionnaire (TFEQ);Gut microbiota;Appetite Visual Analog (VAS);Basal Metabolic Rate (BMR);Waist Circumference (WC);Syndrome Element Analysis in TCM;high-density lipoprotein cholesterol, HDL-C;Food Cravings Questionnaire- Trait (FCQ-T);

Countries

China

Contacts

Public ContactFENG TAO

Shanghai Municipal Hospital of Traditional Chinese Medicine?

taofeng@shutcm.edu.cn021-56639828

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026